Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
